home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Haemonetics Corporation Common Stock (NY:HAE)

71.28 +1.43 (+2.05%)

Official Closing Price Updated: 7:00 PM EDT, Jun 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Haemonetics Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

What Analysts Are Saying About Haemonetics Stock ↗

September 10, 2024

Via Benzinga

Investors should take note of NYSE:HAE, a growth stock that remains attractively priced. ↗

August 28, 2024

Looking for growth without the hefty price tag? Consider NYSE:HAE.

Via Chartmill

Analyst Expectations For Haemonetics's Future ↗

August 22, 2024

Via Benzinga

Top 3 Health Care Stocks That Are Set To Fly This Quarter ↗

August 16, 2024

Via Benzinga

Investors should take note of NYSE:HAE, a growth stock that remains attractively priced. ↗

August 06, 2024

Investors seeking growth at a reasonable cost should explore HAEMONETICS CORP/MASS (NYSE:HAE).

Via Chartmill

Sotera Health Appoints Christopher Simon to the Board of Directors

August 01, 2024

From Sotera Health Services, LLC

Via GlobeNewswire

NYSE:HAE stands out as a growth opportunity that won't break the bank. ↗

July 16, 2024

NYSE:HAE is not too expensive for the growth it is showing.

Via Chartmill

Looking for growth without the hefty price tag? Consider NYSE:HAE. ↗

June 25, 2024

HAEMONETICS CORP/MASS (NYSE:HAE) stands out as a growth opportunity that won't break the bank.

Via Chartmill

NYSE:HAE, a growth stock which is not overvalued. ↗

June 03, 2024

Despite its growth, HAEMONETICS CORP/MASS (NYSE:HAE) remains within the realm of affordability.

Via Chartmill

Haemonetics' Strategic Moves Poised To Boost Margins And Earnings, Says Analyst ↗

June 12, 2024

Analyst upgrades Haemonetics to Buy, believes company can reach high-20% operating margin goal by FY26 through product mix analysis. Price target set at $112.

Via Benzinga

This McCormick Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Wednesday ↗

June 12, 2024

Via Benzinga

These 3 Companies Boast Bright Outlooks ↗

June 05, 2024

Favorable earnings estimate revisions are key for a stock to move higher. Let’s examine a few highly ranked stocks, including Stride, Interactive Brokers, and Haemonetics.

Via Talk Markets

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

May 21, 2024

Via Benzinga

4 Analysts Assess Haemonetics: What You Need To Know ↗

May 10, 2024

Via Benzinga

Earnings Scheduled For February 8, 2024 ↗

February 08, 2024

Companies Reporting Before The Bell • Ares Management (NYSE:ARES) is expected to report quarterly earnings at $1.09 per share on revenue of $864.54 million.

Via Benzinga

Is HAEMONETICS CORP/MASS (NYSE:HAE) suited for quality investing? ↗

October 09, 2023

Why the quality investor may take a look at HAEMONETICS CORP/MASS (NYSE:HAE).

Via Chartmill

Exploring NYSE:HAE's quality characteristics. ↗

September 05, 2023

Should you consider HAEMONETICS CORP/MASS (NYSE:HAE) for quality investing?

Via Chartmill

Should you consider NYSE:HAE for quality investing? ↗

August 10, 2023

HAEMONETICS CORP/MASS (NYSE:HAE) may be suited for quality investing, we'll explore why in this article.

Via Chartmill

HAE Stock Earnings: Haemonetics Beats EPS, Beats Revenue for Q4 2024 ↗

May 09, 2024

HAE stock results show that Haemonetics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2024.

Via InvestorPlace

For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering. ↗

April 05, 2024

For those who appreciate growth without the sticker shock, NYSE:HAE is worth considering.

Via Chartmill

Intuitive Surgical Stock Earns Relative Strength Rating Upgrade; Hits Key Benchmark ↗

November 17, 2023

Intuitive Surgical stock saw a positive improvement to its Relative Strength (RS) Rating on Friday, with an increase from 74 to 85.

Via Investor's Business Daily

Intuitive Surgical Stock Rating Climbs As Sales, Profits Rise ↗

October 16, 2023

Intuitive Surgical stock got an IBD rating upgrade Monday. It edged up 0.37% to 274.16, its second day in a row of rising share price.

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

October 10, 2023

Via Benzinga

4 Analysts Have This to Say About Haemonetics ↗

August 09, 2023

Via Benzinga

Haemonetics Earnings Preview ↗

August 07, 2023

Via Benzinga

Haemonetics Corp. (NYSE: HAE) Making Surprising Moves in Monday Session

July 17, 2023

Via Investor Brand Network

Haemonetics Q4 Earnings Exceed Expectations On Volume And Price Benefits ↗

May 11, 2023

Via Benzinga

Intuitive Surgical Stock Nearly Doubles; Gets Rating Upgrade ↗

September 26, 2023

Intuitive Surgical stock dipped to an intraday low 180.07 in October last year as the bear market ended, then shot up to 358.07 on July 19.

Via Investor's Business Daily

Recap: Haemonetics Q4 Earnings ↗

May 11, 2023

Via Benzinga

Looking Into Haemonetics's Return On Capital Employed ↗

February 08, 2023

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com